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Alzheimer’s disease (AD) is the most common form of dementia affecting the growing 
aging population today, with prevalence expected to rise over the next 35 years. Clinically, 
patients exhibit a progressive decline in cognition, memory, and social functioning due 
to deposition of amyloid β (Aβ) protein and intracellular hyperphosphorylated tau protein. 
These pathological hallmarks of AD are measured either through neuroimaging, cerebro-
spinal fluid analysis, or diagnosed post-mortem. Importantly, neuropathological progres-
sion occurs in the eye as well as the brain, and multiple visual changes have been noted 
in both human and animal models of AD. The eye offers itself as a transparent medium 
to cerebral pathology and has thus potentiated the development of ocular biomarkers 
for AD. The use of non-invasive screening, such as retinal imaging and visual testing, 
may enable earlier diagnosis in the clinical setting, minimizing invasive and expensive 
investigations. It also potentially improves disease management and quality of life for 
AD patients, as an earlier diagnosis allows initiation of medication and treatment. In this 
review, we explore the evidence surrounding ocular changes in AD and consider the 
biomarkers currently in development for early diagnosis.
Keywords: Alzheimer’s disease, neurodegereration, biomarkers, animal models of neurodegenerative disease, 
visual changes
iNTRODUCTiON
The growth in life expectancy and the developing aging population has led to the increased prevalence 
of chronic diseases, such as Alzheimer’s disease (AD). Globally, there are almost 46 million people 
in the world living with dementia, with the number expected to rise to 131.5 million by the year 
2050 (1). According to the World Health Organization (WHO) Global Burden of Disease (2004), 
dementia is the second largest contributor leading to total number of years living with disability 
(YLD) in people aged 60 years or older at 13.5%, compared to heart disease (4.0%), stroke (4.4%), 
and cancer (2.2%) (1).
Pathologically, AD is characterized by deposition of extracellular senile plaques, which is 
composed of amyloid β (Aβ) and intraneuronal neurofibrillary tangles (NFTs), resulting from 
intracellular aggregates of hyperphosphorylated tau protein detected in the brain (2). Aβ plaque 
deposition is associated with cross-sectional synaptic network dysfunction, progressive brain atro-
phy, and longitudinal cognitive decline (3). Studies have shown that Aβ and tau pathology correlates 
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with neurocognition in mild cognitive impairment (MCI) (4). 
Less specific neuropathological lesions include granulovacuolar 
degeneration and eosinophilic rod-like bodies known as Hirano 
bodies (5).
Presently, AD can only be diagnosed post-mortem on histo-
pathological examination. Diagnostic investigations are limited, 
and physicians rely on clinical examination and exclusion of 
differential diagnoses that may cause cognitive impairment, such 
as depression, Parkinson’s disease (PD), hypothyroidism, drug 
interactions, and vitamin deficiencies (6). Clinically, a diagnosis 
is made based on history, examination, and where available, 
accounts from relatives or carers. Nevertheless, premortem diag-
noses have been considered inaccurate in 10–15% of cases even 
when assessed by experienced clinicians (7). Given the difficulties 
and delay in clinical diagnosis, patients often develop pathologi-
cal damage prior to starting treatment. The advance of biomark-
ers using magnetic resonance imaging (MRI), positron emission 
tomography (PET), and cerebrospinal fluid (CSF) have led to the 
development of guidelines and diagnostic criteria (8–10). SPECT 
scanning can also be used to detect regional reduction in cerebral 
blood flow thought to be present in patients with AD (11).
Alzheimer’s disease is a heterogeneous disease and has multiple 
cognitive subtypes. These are usually broken down into memory, 
language, executive, attention, and visuospatial functioning (12). 
The variant of AD in which visual symptoms are prominent due 
to the localized pathology in the parieto-occipital region is often 
referred to as visual variant Alzheimer’s disease (VVAD) (13).
The interconnection between eye and brain suggests that it is 
reasonable to look for ocular manifestations of neurodegenera-
tive disease and regard the eye as an extension of the CNS.
In embryological development, the eyes and brain have a 
similar origin. The eyes are formed from the anterior neural tube, 
an area that later gives rise to the forebrain. Ocular development 
occurs through specification of the eye field post-neural induction 
(14). This process involves specific transcription factors that are 
also conserved in brain development. One such factor, a “master 
regulator” gene of the development of the eye field, Pax6, plays an 
essential role in neural development. When expressed ectopically, 
Pax6 can induce ocular formation in other parts of the body (15), 
whereas its impairment or knockout disrupts neurogenesis in the 
cortex (16, 17).
In the eye, retinal neurons are comparable in many ways to their 
counterparts in the brain. Retinal neurons have dendrites, a soma 
and an axon, which are the essential neuronal features (18). They 
are stained by many typical neuronal markers (19–21). They form 
complex information processing networks similar to those in the 
cerebrum (22–24). The retina contains over 60 types of neuron (25) 
that play distinct roles in information processing. Photoreceptors 
represent one of the five main types of cells, the others being hori-
zontal, bipolar, amacrine, and ganglion cell types. Photoreceptors 
transmit signals in a neuronal fashion when excited by light and 
are separated into two main subtypes, rods and cones. Bipolar 
cells transmit this information to retinal ganglion cells (RGCs). 
Horizontal cells are also connected to photoreceptors as well as 
bipolar cells and provide inhibitory feedback, to both adjust and 
refine the light signal. Amacrine cells can modify direct signals 
between bipolar and ganglion cells or can act as intermediaries 
between the two (26). In retinal networks, amacrine, bipolar, and 
horizontal cells act similar to interneurons, and the RGCs behave 
as projection neurons. Similar classes of neurotransmitters have 
been found in the retina, such as GABA and glutamate, which 
are essential to retinal information processing (27–29). Recently 
discovered group of retinal cell subtype are the intrinsically pho-
tosensitive retinal ganglion cells (ipRGCs). These cells respond to 
light through expression of the photopigment melanopsin in the 
absence of rod and cone photoreceptor input (30).
Therefore, due to its close association with the brain, it is not 
surprising that neurodegeneration caused by disorders such as 
Alzheimer’s extends into the eye. Visual symptoms have been well 
documented in AD, and there is significant evidence to illustrate 
that ocular pathology occurs as part of the disorder (31, 32). 
Consequently, this provides an opportunity to use a minimally 
invasive approach to examine the pathological features in the 
brain – through the transparent medium of the eye.
A critical component of research into AD is the use of animal 
models to standardize and replicate features of the disease in 
order to develop and assess response to treatments that would 
otherwise be unethical in human subjects. Approximately 98% of 
potential drug therapies fail in Phase 3 clinical trials, thus, push-
ing the focus of research toward targeting molecular pathways 
rather than symptom control (33). Animal models need to fit 
three validation criteria when used for human research (34). 
These are face validity, predictive validity, and constructive valid-
ity, which aim to ensure that animal model is based on relevant 
interpretation of the human condition.
With this in mind, many animal models have been proposed, 
including dog, rhesus monkey, Drosophila melanogaster, rat, and 
mouse (35). In particular, the mouse model is the most popular, 
as it has been noted to be most similar to human CNS structure 
in addition to its relatively inexpensive production of multiple 
transgenic strains (36). Transgenic mouse models of AD express 
single, double, or triple mutations found in familial AD. Genes 
encoding these mutations are presenelin 1 (PS1), presenelin 
2 (PS2), tau, and amyloid precursor protein (APP). It is not 
the scope of this review article to detail all transgenic models 
available, but for the reader to have a brief background into the 
mutations involved.
There is a growing interest to identify a biomarker for AD 
to enable early diagnosis and prevent cognitive deterioration 
in patients. Genetic testing in AD has identified three genetic 
loci, APP, presenilin-1 (PSEN1), and presenilin-2 (PSEN2) as 
susceptibility genes for early-onset AD (EOAD) and SORL1 
and APOE for late-onset AD (LOAD). Although these genes 
are useful in predicting the risk of developing AD, their lack of 
diagnostic specificity and sensitivity and the influence of external 
environmental factors make them unsuitable as biomarkers for 
AD (37–39). The majority of research has focused on the retina 
and associated changes in thickness, inflammation, and cell 
death. Nevertheless, manifestations of AD have additionally been 
identified in the pupil, lens, choroid, and optic nerve, though 
their use in the clinical setting has not been established (Table 1). 
Furthermore, changes in visual function have been identified 
in multiple studies (Table 2) and are also being investigated as 
potential indicators of AD pathology.
TABLe 1 | Manifestations of Alzheimer’s disease (AD) in the eye.
Orbital 
structure
Pathological changes in AD
Pupil Atypical pupil response to cholinergic antagonists (53, 54)
Lower amplitude and latency of maximum reaction of 
pupillary light reflex (59)
Increased pupillary size (62)
Lens Aβ in lens and aqueous humor (66)
Predisposition to supranuclear cataract (66)
Retina Decreased retinal blood flow and RNFL thinning (75, 82, 83)
RGC degeneration particularly in superior and inferior 
peripheral retina (100, 106)
Overall reduction in RGC axon numbers (26)
Aβ deposition in retina (94)
Choroid Reduced choroidal thickness (101)
Optic nerve Increased cup: disk ratio and pallor (148–150)
TABLe 2 | visual manifestations of AD.
indicator of 
vision
Manifestation of AD Recommended 
clinical testa
Visual acuity Decreased visual acuity in low 
luminance (32, 33)
HOTV chart
Contrast 
sensitivity
Reduced visual contrast sensitivity 
particularly in low frequencies (37, 38)
Pelli–Robson  
chart (35)
Reduced reading speed at lower 
contrast sensitivities (37)
Michelson contrast 
test (37)
Color vision Poor color discrimination (43) City University test
Deficiencies most significant in tritan 
axis (31, 42)
Ishihara test (154)
Visual field 
loss
Inferior hemifield loss (45) Humphrey automated 
perimetry (45)
FDT (46)
Motion 
perception
Higher thresholds for motion detection 
across all spatial frequencies (57)
Computer animation 
sequences using 
random dot 
cinematogram (57)
Depth 
perception 
and 
stereopsis
Reduced stereopsis, mean threshold 
>150 s of arc
Randot stereotest (155)
Ocular motor 
function
Abnormal hypometric saccades Eye movement 
examination (62)Increased latency as compared to 
controls (50, 51)
aAll clinical tests require patient cooperation, which can be difficult in AD patients.
AD, Alzheimer’s disease; FDT, frequency doubling technique.
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viSUAL MANiFeSTATiONS OF AD
visual Acuity
Many studies have found no significant difference in visual acuity 
between AD patients and control subjects (40). Levels of lumi-
nance may affect visual acuity, as demonstrated in AD patients 
who had decreased visual acuity under conditions of low lumi-
nance (LL) (41, 42). A recent study has shown that AD patients 
have a significantly poorer accuracy and ability in recognition 
of pictures in LL and low spatial frequency (LSF), compared to 
age-matched controls (43). Another important factor to note in 
AD patients is the increased prevalence of cataract affecting visual 
acuity, which is addressed later in this review (44).
Contrast Sensitivity
Contrast sensitivity allows for the ability to recognize objects 
over a range of spatial frequencies and is usually tested using 
charts (45) or electronic equipment. A deficit in this visual 
function greatly affects the daily functioning and quality of life 
and may explain the increased risk of falls and fractures in AD 
patients (46). AD patients have markedly reduced visual contrast 
sensitivity as compared to age-matched controls (47, 48) and 
are sensitive to testing even in early stages of AD. Furthermore, 
donepezil, an anticholinesterase inhibitor, has been shown to 
improve contrast sensitivity in AD patients (49). A reduction in 
reading speed has also been noted, particularly at lower contrast 
sensitivities (47). Studies have also shown that reading latency 
is increased in AD patients and is more evident with irregular 
words in text (50).
Color vision
Köllner first described changes in color vision, according to area 
of the eye affected, correlating retinal disease with blue–yellow 
visual changes and optic nerve disease with red–green visual 
loss (51). Earlier studies in AD patients have indicated that there 
are deficiencies in the tritan (blue) axis (40, 52), but more 
recent studies show no significant interaction in color axes (53). 
However, they do report an inversely proportional correlation 
with mini-mental state examination (MMSE) score and color 
discrimination error.
visual Field Loss
Visual field (VF) loss in AD is likely attributed to the neurode-
generative changes and synaptic dysfunction, particularly due 
to Aβ accumulation (54). Humphrey automated perimetry has 
been used in VF testing between AD patients and age-matched 
controls and has shown that the sensitivity losses occur particu-
larly in the inferior hemifield of AD patients, and furthermore 
that degree of loss correlated with degree of dementia (55). VF 
testing with frequency doubling technology (FDT) also found 
that AD patients had VF deficits as compared to age-matched 
controls (56).
Motion Perception
Motion perception is the process of deducing speed and direction 
of elements and is vital to everyday functioning and navigation. 
Studies have detected higher thresholds for motion detection in 
AD patients as compared to age-matched controls, and further 
correlation with dementia severity (57). Another recent study 
looked at visual motion processing and again found that patients 
with AD had higher thresholds across all spatial and temporal 
frequencies (58).
Depth Perception and Stereopsis
Stereopsis is the perception of depth and 3D structure obtained 
from binocular vision. Studies have shown that patients with AD 
have reduced stereopsis as compared to control groups, and some 
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also note a correlation between cognitive assessment scores and 
performance on stereopsis testing (59, 60).
Ocular Motor Function
Alzheimer’s disease patients are known to have ocular motility 
dysfunctions and poor visual attention. They are often unable 
to focus on a fixed object, due to their difficulty in suppressing 
reflexive saccades. Crawford et al. used “eye tracking” software 
to assess saccadic eye movements in AD patients and found that 
they had slower reaction times as compared to the control group 
(61). Other studies have also shown patients with AD presented 
with abnormal hypometric saccades when tested, in addition to 
increased latency as compared to controls (62, 63). In particu-
lar, anti-saccades require movement of the eye in the opposite 
direction of a visual stimulus and suppression of the reflexive 
response. Functional MRI (fMRI) studies have shown patients 
with AD exhibited significantly more anti-saccade errors and, 
overall, demonstrated reduced activity in all oculomotor regions 
of the brain as compared to controls (64). The convergence angle 
has also been noted to be smaller and more irregular in AD 
patients (65).
PUPiL
It is now well established that patients with AD have an acetyl-
choline deficit and an altered ACh pathway (66). This became 
apparent in 1994 as a hypersensitive pupil response to cholin-
ergic antagonist, tropicamide (0.01%), was discovered (67). AD 
patients’ pupils dilated to 13% more than controls. Subsequent 
experiments by Iijima et al. (68) found that significant differences 
in pupil sizes were found at a lower dose of tropicamide (0.005%), 
potentiating the possibility for a diagnostic screening test. Scinto 
(69) further investigated pupil involvement in AD and located 
a clear biological link between ApoE allele status and pupillary 
response to dilute tropicamide. Nevertheless, the use of the tropi-
camide test as a diagnostic tool for AD is controversial, as other 
studies have failed to find significant results (70–72).
Another indicator of AD pathology is the pupillary light reflex 
(PLR). Changes in the oculomotor system of the Edinger–Westphal 
nucleus and degeneration in the nucleus basalis of Meynert 
leading to cholinergic deficit are likely to lead to changes in the 
pupillary system. Pupillometry using image analysis technology 
can provide multiple parameters from a single PLR test, such as 
latency to pupil reaction, constriction acceleration and velocity, 
and amplitude of response. Prettyman et al. first described 75% 
latency of normal pupil size and the differences in constriction 
amplitude between AD patients and controls (73). Repetitive 
stimulation of the pupil light reflex over time is less pronounced 
in AD patients as compared to controls, with lower amplitude 
and latency of maximum reaction (74). Certain PLR measures 
have been found to correlate with cerebral plaque burden (75). 
Moreover, Bittner et al. found a significant correlation between 
increased pupillary size and CSF measures of both Aβ and tau 
(76). Color pupillometry has been used to measure the response 
of ipRGCs in various eye disorders (77, 78), but not yet tested in 
AD patients. This may be a potential biomarker requiring further 
investigation in future studies.
LeNS
Interest in the lens as an indicator of AD began after APP and Aβ 
expression were discovered in cultured mammalian lenses (79). 
In animal models, Aβ transgenic mice have developed lens opaci-
fication and shown to improve with EUK-189, a synthetic SOD/
catalase, demonstrating a link between AD-associated cataracts 
and oxidative stress (80). Dutescu et  al. also noted significant 
Aβ deposition in the lens of transgenic mice when labeling with 
WO2 and 1E8 antibodies, consistent with results from human 
studies (81).
In humans, Goldstein et al. detected the presence of Aβ in the 
lens and aqueous humor of AD patients (82). They also found 
that AD patients had a specific cataract in the supranuclear 
region not present in controls, which had high reactivity and 
staining against Aβ markers and antibodies. Similar cataracts 
have been found in Down syndrome patients, who have an 
increased level of Aβ due to a triplication of the APP gene (83). 
However, Michael et  al. (84, 85) and Ho et  al. (86) found no 
staining of Aβ in the lens of AD patients, although using different 
staining and characterization methodologies (84–86). Moreover, 
in a recent study, Bei et al. have concluded that opacities of the 
lens cannot be used as a non-invasive risk marker, as it does not 
vary significantly when controlling for age (87). Nonetheless, a 
clinical study by Kerbage et al. found that a fluorescent ligand 
for Aβ could be used in vivo to differentiate between AD patients 
and controls (88). There was a twofold greater signal in the AD 
patients compared to controls.
A subsequent clinical trial found the fluorescent signal of 
the same ligand to be able to distinguish between clinically 
diagnosed AD patients and controls with better results than 
a PET marker (89). This is a promising new development for 
diagnosing Alzheimer’s, although few studies have investigated 
changes during early stages of the disease. The incidence of 
cataracts and AD increases with age. This is important to note 
when using the lens as a biomarker for AD, as many patients will 
develop cataract irrespective of AD and, furthermore, may have 
undergone cataract surgery, thus limiting the use of the lens as 
a biomarker.
ReTiNA
Retinal vasculature
Similar to the brain, the retina has a highly isolated and thor-
oughly protected vasculature (90). Since there are vascular 
changes in the AD brain (91), it is likely that the analogous 
changes may be found in the AD retina. In a preliminary study, 
Berisha et  al. found decreased vein diameter and decreased 
blood flow (92). In two recent large-scale studies (n =  456), 
AD patients had a less complex venular structure, smaller, 
more sparse, and tortuous retinal vessels (93, 94). Furthermore, 
recent studies have found significantly decreased retinal 
venous blood flow in AD patients (95). Importantly, MCI 
patients’ blood flow was found to be intermediate between 
AD patients and controls. This suggests that retinal blood 
flow (microliter per minute) might be used to monitor disease 
progression. They also observed that retinal nerve fiber layer 
TABLe 3 | Location of APP and Aβ found in the animal retina.
Retinal layer APP Aβ Tau
Retinal pigment epithelium − − −
Outer nuclear layer − + −
Inner nuclear layer + + −
Inner plexiform layer + + −
Ganglion cell layer + + +
+Present.
−Absent.
APP has been found in the ganglion cell layer through the inner nuclear layer in AD 
animal models (65, 81, 86, 106). Aβ has been found in the retina in all layers apart from 
the retinal pigment epithelium (81, 88, 93, 109, 114). Tau has been found in ganglion 
cell layer (99, 106, 133).
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(RNFL) thickness was decreased, but not significantly between 
AD patients and both MCI and control groups. This suggests 
that blood flow changes may precede cell death in the retina. 
Retinal oximetry is used to detect changes in eye metabolism 
and has been noted in a recent study to show abnormalities in 
AD. Einarsdottir et al. found that retinal oxygen saturation in 
arterioles and venules was elevated in AD patients as compared 
to controls (96).
Retinal Thickness
Early histopathological studies implicated RGCs as the primary 
targets of cell loss in AD (97). As they demonstrated that the 
outer layers were relatively preserved in the postmortem retinas 
of AD patients, measurements have predominantly focused 
on the RNFL. Imaging technology, such as optical coherence 
tomography (OCT), has recently illustrated further evidence of 
RGC degeneration in vivo through measurement of the RNFL, 
indirectly evidencing ganglion cell loss (92, 98–100). An initial 
study by Parisi et al. found decreased RNFL thickness in all four 
retinal quadrants (101). RNFL thinning correlated with patients’ 
pattern electroretinogram performance, suggesting that RNFL 
thinning is related to visual dysfunction in AD. Current evidence 
also suggests that RNFL thickness decreases as the disease pro-
gresses and that there is a significant correlation between overall 
macula volume and level of cognitive impairment measured by 
the MMSE (102). Studies have shown significant differences not 
only between MCI patients and controls but also between MCI 
patient’s and two other AD groups (moderate and severe AD) in 
superior and total RNFL thickness (103). A recent meta-analysis 
(104) of 11 AD OCT studies found significant reduction in 
mean RNFL and in all 4 individual retinal quadrants around the 
AD macula. In three of these studies containing MCI patients, 
decreased RNFL thickness was found compared to controls. 
Bambo et al. also noted significant RNFL thinning in the superior 
and inferior quadrants of AD patients (105).
A few animal studies have published similar findings with 
regards to neuronal cell loss in the RGCL. One study using a 
single transgenic mouse model reported a statistically significant 
decrease in the retinal thickness of the Tg2576 mice from the 
GCL to the ONL as compared to wild-type control animals (106). 
This suggests that retinal degeneration may affect all retinal cell 
types and layers.
Recently, Ong et  al. (107) combined the use of OCT and 
MRI scanning in an elderly population (>60  years old). They 
discovered that decreases in GC-IPL thickness correlated with 
decreased size of the occipital and temporal regions of the brain. 
These correlations suggest that degeneration in the retina is paral-
leled in specific regions of the brain, which are implicated in AD.
Aβ in the Retina
Synaptic dysfunction and neuronal cell death because of Aβ toxic 
deposits are pathological hallmarks of AD (54). In animal mod-
els, overexpression of the human APP Swedish gene in Tg2576 
mouse results in deposition of Aβ plaques in the brain (81). This 
strain of mice developed memory deficits at 10 months of age as 
compared to the APPswe/PS1-del9 transgenic strain that devel-
oped deficits earlier at 6 months of age (108). Aβ plaques have 
since been reported in the same strain, from the ganglion cell 
layer to the inner plexiform layer, in addition to plaques found 
in the outer segment and optic nerve (106, 109) (Table 3). Thus, 
this model suggests that ganglion cells and potentially retinal 
interneurons (horizontal, bipolar, and amacrine cells) are affected 
by Aβ plaques; yet, all retinal cells may be compromised in later 
stages of the disorder.
Amyloid β loads are further associated with immunoreactivity 
for MCP-1, F4/80, and TUNEL-positive profiles in the RGC layer 
in mutant presenilin (PS1) and APP transgenic mice. This further 
indicates that Aβ deposition causes retinal neurodegeneration in 
mouse models of AD (110). Transgenic mice overexpressing the 
Swedish mutation (APP23) and mutant human APP and mutant 
human presenilin-1 (APPPS1) exhibit a threefold increase in 
total endogenous murine Tau in CSF and an age-related increase 
in Aβ deposition (111).
In vivo imaging in APP/PS1 transgenic mice following admin-
istration of systemic curcumin has provided a potential tool for 
monitoring Aβ plaque formation in AD (112). Optical imaging 
showed increased plaque formation with age in the mouse model, 
and remarkably, a decrease in response to glatiramer acetate 
immunotherapy. APP and Aβ have both been located in the human 
retina (113); however, these were not consistently found (32). A 
major advance was made in 2011 in human AD, where Aβ was 
visualized in the postmortem retina and also live animal retina 
(114). Very recent work has revealed substantial Aβ deposition in 
postmortem AD retinas and that these deposits may preferentially 
target the melanopsin-staining subtype of RGC (115).
Amyloid β has been identified in retinal drusen, a hallmark 
of age-related macular degeneration (AMD), a major cause of 
worldwide blindness. Drusen are abnormal extracellular depos-
its along the basal surface of the retinal pigmented epithelium 
(RPE). Aβ-containing drusen are associated with RPE atrophy 
and photoreceptor death (116, 117). In AMD, they are predomi-
nantly located in the macula at the center of the retina, but they 
can still occur peripherally. In fact, peripheral drusen have been 
found to be significantly associated with AD (118, 119).
It is believed that Aβ can enter the RPE through advanced gly-
cation end products (RAGE)/p38 MAPK-mediated endocytosis. 
Intracellular Aβ triggers breakdown of RPE tight junctions (120), 
as described in Tg AD mice (121). The toxic effects of Aβ on RPE 
include reduced mitochondrial redox potential and increased 
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reactive oxygen species (ROS) production, RPE pigmentation and 
hypertrophy, followed by photoreceptor death (122). In addition, 
Aβ-mediated gliosis of Müller cells (MCs) has been implicated in 
retinal degeneration. MCs are the principal retinal glial cells and 
metabolically coupled to photoreceptors. Glial cell activation in 
response to Aβ deposition has compromised the integrity of the 
blood–retina barrier, leading to photoreceptor apoptosis (123). 
Interestingly, Aβ did not induce cell death in purified photore-
ceptor cell cultures but in mixed retinal cell cultures, suggesting 
that the cellular environment plays a role in Aβ-mediated photo-
receptor apoptosis (124). Furthermore, Aβ has been implicated 
in complement activation by upregulating factor B, the main 
activator of the complement alternative pathway, in RPE through 
cytokines, which are released from recruited macrophages/
microglia (125). This may explain the colocalization of Aβ with 
activated complement components found in some drusen (126, 
127). Similar observations have also been reported in senile Aβ 
plaques in the brain, where Aβ is thought to be a primary activa-
tor of complement in AD (128), suggesting common mechanisms 
may be applied to AD, drusen formation, and AMD.
Tau in the Retina
Tau accumulation has been observed in brains of doubly trans-
genic mice from 4.5 months of age (129) and in the hippocampus 
and amygdala of triple-transgenic mice (130). In single Tg2576 
transgenic mice (APP), hyperphosphorylated tau was observed 
in adjacent sections of Aβ deposition in the ganglion cell layer 
(106). Double-transgenic mice APP/PS1 also displayed hyperex-
pression of tau in the retina with consequent upregulation of p35, 
p25, and calpain, which has been widely hypothesized to cause 
synaptic dysfunction and calcium dysregulation in the context 
AD-related apoptosis (131, 132). In human P301S tau transgenic 
mice, tau aggregates formed in the RNFL resulting in axonopathy 
and at 2 months of age formed tau inclusions within RGC (133). 
Tau has been found in the human retina (113); yet, this finding 
has not been consistently replicated (86, 134).
Retinal Fluorescence and 
Neurodegeneration
In animal models, retinal changes observed in double-transgenic 
mice included accumulation of Aβ peptides in addition to detec-
tion of apoptotic cells in the RGC layer (135). Another study 
using the double-transgenic model (Tg2576 ×  Tg1) observed 
that 27-month-old mice had a 200% increase in the number 
of apoptosing cells in the GCL, as compared to 7.8-month-old 
mice (110).
A more extensive triple-transgenic mouse model expressing 
human APP, PS1, and tau mutations was used to investigate 
retinal glial changes in AD. The study by Edwards et al. found 
that at 9 months, MCs were activated, and astrocytes increased in 
size and number indicating retinal glial activation (136). Further 
evidence for involvement of the outer retina in AD models of 
disease is depicted in transgenic AD rat models. Tsai et al. found 
on staining of retinal sections that RPE cells showed marked 
hypertrophy and frequently contained two nuclei rather than 
one (137).
In vivo imaging has recently developed to allow direct visu-
alization of apoptosing cells in the retina. A novel technique has 
been established using radiolabeled annexin V and confocal laser 
scanning ophthalmoscopy to detect cell apoptosis in the retina 
(138). This in  vivo imaging method is known as detection of 
apoptosing retinal cells (DARC). Using this imaging technique 
and applying it to animal models provides further evidence of 
RGC apoptosis in AD. Following PI and annexin-IR intravitreal 
injection in triple-transgenic AD mice, a significant number of 
RGCs were observed to undergo early-phase apoptosis as com-
pared to age-matched controls (139).
A small pilot study using retinal fluorescence lifetime imaging 
ophthalmoscopy (FLIO) suggested that retinal changes detected 
by FLIO correlated with clinical characteristics of AD and could 
potentially be used as a biomarker for AD. However, the lack 
of control group and small study size warrants further research 
before attributing these general changes specifically to AD (140). 
Another study used systemic curcumin administration followed 
by optical imaging to successfully label retinal Aβ plaques in mice 
(114). This has also been trialed in patients using curcumin sup-
plements and retinal fluorescence imaging (141). Furthermore, 
recent research has established methods of identifying drusen 
deposits in the peripheral retina using ultra-wide-field imaging 
(142, 143). This is particularly of note in patients with AD, as 
these small deposits were not found in age-matched controls, 
thus providing possibility for another potential biomarker for 
diagnosis of early AD.
CHOROiD
Most research has been directed toward retinal changes in AD 
given the direct association with the brain. However, a few studies 
have observed possible choroidal manifestations of AD in animal 
models. Heterozygous transgenic rats (TgF344-AD) had signifi-
cantly reduced choroidal thickness as compared to age-matched 
controls (137). Also, of note in this particular study was the 
upregulation of complement factor C3, which has previously been 
noted to play a role in RGC related apoptosis, studied particularly 
in glaucoma (144). Ning et al. also reported age-dependent Aβ 
deposits in the retinal and choroidal vasculature of two strains of 
transgenic mice (110).
In human models, recent imaging of the choroid in AD 
patients showed decreased choroidal thickness (145). However, 
given the limited research undertaken, more studies are needed 
to confirm if the choroid is indeed damaged in AD.
OPTiC NeRve AND 
NeURODeGeNeRATiON
Cell death of RGC and changes in the optic nerve head have 
long been noted in postmortem AD retinas and first described 
by Hinton et al. who found a variety of degenerative profiles in 
RGCs, including cell shrinkage and cell swelling with vacuoli-
zation (97). Moreover, there was a two to threefold reduction 
in RGC axon numbers compared to controls. Further research 
(146) found the same features of degeneration in addition to 
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nuclear fragmentation and heavily silver-stained cytoplasm. 
It was also noted that AD optic nerves had approximately half 
the RGC axon density of controls (32). This suggests that the 
larger “M” cell type RGCs are chiefly affected by AD. Blanks et al. 
found a 25% reduction of RGCs in the central 3 mm of the AD 
retina and severe cell loss over the entire retina (134, 147). This 
degeneration is more pronounced in the superior and inferior 
peripheral regions.
More recently, new imaging technologies have provided in vivo 
evidence of optic nerve head pathology. Multiple studies, using 
OCT and confocal laser scanning, have found greater cup-to-disk 
ratio and increased pallor of the AD optic nerve, representing a 
significant loss of RGC axons (148–151).
FUTURe iMPLiCATiONS
As outlined earlier in this review article, specialist brain imag-
ing modalities, such as fMRI and PET scanning, can support 
a diagnosis of AD. Unfortunately, these are expensive inves-
tigative techniques and are often limited to a hospital setting. 
Furthermore, changes in the brain are often a sign of later-stage 
AD and symptoms of cognitive decline will already have set in. 
Remarkably, studies now support the hypothesis that Aβ plaques 
appear earlier in the retina (114) and so propose the possibility for 
earlier diagnosis of AD and subsequent treatment.
Alzheimer’s disease-related retinal degeneration has provided 
a novel technique for investigating AD pathology and targeting 
treatment. Multiple human and animal studies have illustrated 
the correlation of AD neuropathology in the retina and the 
brain, including Aβ and tau accumulation, neuronal cell loss, 
and RGC apoptosis. Using the eye and its transparent medium as 
an “extension of the brain” allows for non-invasive visualization 
of AD pathology in vivo, and enables monitoring of biomarkers 
in order to diagnose and potentially monitor development and 
treatment of AD.
Technology, such as DARC, has provided a platform for this 
(139), and different approaches to in  vivo imaging are con-
stantly evolving (114, 143, 152). Unfortunately, these methods 
of in  vivo imaging are not without limitations, particularly 
with regards to specificity for Aβ plaques. Currently, the use 
of OCT to assess the ONH and RNFL are useful in detect-
ing neurodegeneration, in addition to a comprehensive eye 
examination in the clinical setting covering VF defects, pupil-
lometry, and contrast sensitivity. In vivo imaging is emerging 
as a potential biomarker in many neurodegenerative diseases 
(138, 153), and the evolution and development of such imag-
ing techniques today prove promising as diagnostic tools of 
the future.
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